Payment overview · 2025
General Payments
$166.98
4 reported records · 4 companies
Healthcare provider profile · identity verified
David S Bridges
Allopathic & Osteopathic Physicians|Family Medicine · GREENWOOD, SC · NPI 1598720112
Verified facts
What the public records show
CMS Open Payments records show David S Bridges received $166.98 in general payments during 2025 across 4 reported records.
AngioDynamics, Inc. accounted for 67.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $111.79 | 67.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.54 | 14.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.23 | 9.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.42 | 9.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $166.98 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $111.79 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 623 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 459 | 130 |
| Atorvastatin Calcium | Atorvastatin Calcium | 421 | 115 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 352 | 94 |
| Meloxicam | Meloxicam | 283 | 63 |
| Zolpidem Tartrate | Zolpidem Tartrate | 263 | 41 |
| Alprazolam | Alprazolam | 205 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 203 | 57 |
| Metformin Hcl | Metformin Hcl | 197 | 54 |
| Omeprazole | Omeprazole | 185 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 180 | 48 |
| Pregabalin | Pregabalin | 179 | 41 |
| Lisinopril | Lisinopril | 171 | 53 |
| Famotidine | Famotidine | 164 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 161 | 44 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 158 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 147 | 37 |
| Gabapentin | Gabapentin | 136 | 34 |
| Tramadol Hcl | Tramadol Hcl | 132 | 39 |
| Ozempic | Semaglutide | 129 | 29 |
| Furosemide | Furosemide | 124 | 41 |
| Prednisone | Prednisone | 122 | 93 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 115 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 29 |
| Jardiance | Empagliflozin | 105 | 24 |
| Potassium Chloride | Potassium Chloride | 103 | 30 |
| Clonazepam | Clonazepam | 101 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 99 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 29 |
| Lansoprazole | Lansoprazole | 94 | 26 |
| Losartan Potassium | Losartan Potassium | 91 | 29 |
| Alendronate Sodium | Alendronate Sodium | 90 | 25 |
| Spironolactone | Spironolactone | 90 | 27 |
| Mounjaro | Tirzepatide | 88 | 14 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 84 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 83 | 37 |
| Diazepam | Diazepam | 78 | 11 |
| Eliquis | Apixaban | 76 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 76 | 20 |
| Carvedilol | Carvedilol | 75 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 73 | 14 |
| Ezetimibe | Ezetimibe | 71 | 23 |
| Januvia | Sitagliptin Phosphate | 70 | 18 |
| Linzess | Linaclotide | 69 | 25 |
| Simvastatin | Simvastatin | 68 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 67 | 17 |
| Warfarin Sodium | Warfarin Sodium | 63 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 62 | 11 |
| Azithromycin | Azithromycin | 61 | 52 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 61 | 13 |
| Trulicity | Dulaglutide | 61 | 11 |
| Montelukast Sodium | Montelukast Sodium | 60 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 27 |
| Nebivolol Hcl | Nebivolol Hcl | 57 | 17 |
| Bupropion Xl | Bupropion Hcl | 53 | 12 |
| Allopurinol | Allopurinol | 49 | 14 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 49 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 21 |
| Donepezil Hcl | Donepezil Hcl | 48 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | suppressed |
| Cefdinir | Cefdinir | 47 | 40 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 45 | 13 |
| Atenolol | Atenolol | 45 | 12 |
| Levofloxacin | Levofloxacin | 44 | 37 |
| Trazodone Hcl | Trazodone Hcl | 42 | suppressed |
| Fluconazole | Fluconazole | 41 | 24 |
| Meclizine Hcl | Meclizine Hcl | 41 | 14 |
| Sertraline Hcl | Sertraline Hcl | 41 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 31 |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 35 | 12 |
| Temazepam | Temazepam | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Baclofen | Baclofen | 34 | suppressed |
| Cilostazol | Cilostazol | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | 11 |
| Gemfibrozil | Gemfibrozil | 32 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 32 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | suppressed |
| Alprazolam Er | Alprazolam | 31 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 31 | suppressed |
| Nystatin | Nystatin | 30 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Bumetanide | Bumetanide | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | 11 |
| Glipizide Er | Glipizide | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Etodolac | Etodolac | 14 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Indomethacin | Indomethacin | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Lamotrigine Er | Lamotrigine | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $166.98 · 4 records | AngioDynamics, Inc. | AURYON LASER SYSTEM 100-120 VAC, Kerendia, TRELEGY ELLIPTA, XIFAXAN | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error